Castleark Management’s Genomic Health, Inc. GHDX Stock Holding History

Castleark Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-95,099	Closed	-$6.66M	–	422
2019 Q1	$6.66M	Buy	95,099 +1,784	+2%	+$132K	0.25%	130
2018 Q4	$6.01M	Sell	93,315 -62,220	-40%	-$4.36M	0.26%	124
2018 Q3	$10.9M	Buy	155,535 +29,150	+23%	+$1.71M	0.31%	108
2018 Q2	$6.37M	Buy	+126,385	New	+$5.01M	0.2%	164

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Castleark Management's GHDX Position: Q2 2019 in Review

Castleark Management sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 95,099 shares — an estimated $6.66M sold.

Castleark Management first reported a position in GHDX in Q2 2018 and held it in 4 quarters. The position peaked at $10.9M in Q3 2018. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

Castleark Management reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
Castleark Management sold 95,099 Genomic Health, Inc. shares in Q2 2019, an estimated $6.66M.
Castleark Management first reported a position in Genomic Health, Inc. in Q2 2018 and held it in 4 quarters.
Castleark Management's Genomic Health, Inc. position peaked at $10.9M in Q3 2018.
215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Castleark Management's 13F filing for Q2 2019, filed 13 Aug 2019.